Clinical Trial: A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07816198) titled 'A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy' on Sept. 07.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes Mellitus (T2DM)

Intervention: DRUG: AD-233A

PO, Once daily(QD), 24 weeks

DRUG: AD-233B

PO, Once daily(QD), 24 weeks

DRUG: AD-233C

PO, Once daily(QD), 24 weeks

DRUG: AD-233D

PO, Once daily(QD), 24 weeks

DRUG: AD-233A Placebo

PO, Once daily(QD), 24 weeks

DRUG: AD-233B Placebo ...